NCT06423911

Brief Summary

Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure criteria while receiving bosutinib in Part A may be able to receive olverembatinib in crossover follow-on study.

Trial Health

88
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
333

participants targeted

Target at P50-P75 for phase_3

Timeline
22mo left

Started Feb 2024

Typical duration for phase_3

Geographic Reach
16 countries

163 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress60%
Feb 2024Jul 2028

Study Start

First participant enrolled

February 5, 2024

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 16, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 21, 2024

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 10, 2028

Last Updated

September 15, 2026

Status Verified

September 1, 2026

Enrollment Period

3.4 years

First QC Date

May 16, 2024

Last Update Submit

September 10, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • 24-Week MMR Rate (Part A)

    To compare the major molecular response (MMR) rate at 24 weeks for olverembatinib versus bosutinib

    24 weeks

  • 24-Week MMR Rate (Part B)

    To evaluate the MMR rate by 24 weeks for olverembatinib in CML-CP patients with T315I mutation

    24 weeks

Secondary Outcomes (10)

  • 96-Week MMR Rate (Part A)

    96 weeks

  • 96-Week MMR Rate (Part B)

    96 weeks

  • Cytogenic Response Rate (Part A)

    Through 96 weeks (i.e., at 24, 48, and 96 weeks)

  • Cytogenic Response Rate (Part B)

    Through 96 weeks (i.e., at 24, 48, and 96 weeks)

  • Progression Free Survival (PFS) (Part A)

    5 years after the last patient received the first study dose

  • +5 more secondary outcomes

Study Arms (2)

Part A, RCT, olverembatinib arm and bosutinib arm

OTHER

Randomized controlled part that is designed to compare the efficacy and safety of olverembatinib (investigational arm) versus bosutinib (control arm) in patients with CML-CP, previously treated with at least two TKIs

Drug: olverembatinibDrug: Bosutinib

Part B, SAT, olverembatinib arm

OTHER

To evaluate the efficacy and safety of olverembatinib in the CML-CP patients with T315I mutation previously

Drug: olverembatinib

Interventions

olverembatinib QOD

Part A, RCT, olverembatinib arm and bosutinib armPart B, SAT, olverembatinib arm

Bosutnib QD

Part A, RCT, olverembatinib arm and bosutinib arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years old
  • Diagnosis of CML-CP
  • Part A: Previously treated with at least two approved TKIs; Part B: T315I mutation at screening and previously treated with at least one approved TKI, with no other effective and/or tolerable therapies available
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
  • Patient has adequate organ function

You may not qualify if:

  • Patients eligible for this study must not meet any of the following criteria:
  • For Part A only: T315I or V299L mutation at any time prior to starting study treatment
  • Active infection that requires systemic drug therapy
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of study drugs
  • Previous treatment with or known / suspected hypersensitivity to olverembatinib or any of its excipients
  • Previous treatment with or known / suspected hypersensitivity to bosutinib or any of its excipients
  • Pregnant or nursing (lactating) women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (163)

Ascentage Investigative Site #1044

Birmingham, Alabama, 35249, United States

RECRUITING

Ascentage Investigative Site #1112

Anchorage, Alaska, 99508, United States

RECRUITING

Ascentage Investigative Site #1111

Goodyear, Arizona, 85338, United States

RECRUITING

Ascentage Investigative Site #1062

Duarte, California, 91010, United States

RECRUITING

Ascentage Investigative Site #1099

Irvine, California, 92618, United States

RECRUITING

Ascentage Investigative Site #1075

La Jolla, California, 92037, United States

RECRUITING

Ascentage Investigative Site #1100

Long Beach, California, 90813, United States

RECRUITING

Ascentage Investigative Site #1059

Los Angeles, California, 90024, United States

RECRUITING

Ascentage Investigative Site #1121

Sacramento, California, 95817, United States

RECRUITING

Ascentage Investigative Site #1109

Upland, California, 91786, United States

RECRUITING

Ascentage Investigative Site #1045

Augusta, Georgia, 30912, United States

RECRUITING

Ascentage Investigative Site #1110

Newnan, Georgia, 30265, United States

RECRUITING

Ascentage Investigative Site #1055

Chicago, Illinois, 60637, United States

RECRUITING

Ascentage Investigative Site #1095

Decatur, Illinois, 62526, United States

RECRUITING

Ascentage Investigative Site #1069

Indianapolis, Indiana, 46237, United States

RECRUITING

Ascentage Investigative Site #1065

Wichita, Kansas, 67214, United States

RECRUITING

Ascentage Investigative Site #1084

Lexington, Kentucky, 40536, United States

RECRUITING

Ascentage Investigative Site #1058

Louisville, Kentucky, 40202, United States

RECRUITING

Ascentage Investigative Site #1801

Baltimore, Maryland, 21201, United States

RECRUITING

Ascentage Investigative Site #1056

Detroit, Michigan, 48201, United States

RECRUITING

Ascentage Investigative Site #1023

Detroit, Michigan, 49254, United States

RECRUITING

Ascentage Investigative Site #1088

St Louis, Missouri, 63108, United States

RECRUITING

Ascentage Investigative Site #1097

Lincoln, Nebraska, 68506, United States

NOT YET RECRUITING

Ascentage Investigative Site #1066

Las Vegas, Nevada, 89169, United States

RECRUITING

Ascentage Investigative Site #1113

Reno, Nevada, 89511, United States

RECRUITING

Ascentage Investigative Site #1064

Hackensack, New Jersey, 07601, United States

RECRUITING

Ascentage Investigative Site #1054

Morristown, New Jersey, 07960, United States

RECRUITING

Ascentage Investigative Site #1098

New Brunswick, New Jersey, 08901, United States

RECRUITING

Ascentage Investigative Site #1072

Albuquerque, New Mexico, 87102, United States

RECRUITING

Ascentage Investigative Site #1068

Rochester, New York, 14642, United States

RECRUITING

Ascentage Investigative Site #1053

Shirley, New York, 11967, United States

RECRUITING

Ascentage Investigative Site #1160

Stony Brook, New York, 11794, United States

NOT YET RECRUITING

Ascentage Investigative Site #1019

Greenville, North Carolina, 27858, United States

NOT YET RECRUITING

Ascentage Investigative Site #1043

Morrisville, North Carolina, 27560, United States

RECRUITING

Ascentage Investigative Site #1173

Cleveland, Ohio, 44111, United States

NOT YET RECRUITING

Ascentage Investigative Site #1096

Cleveland, Ohio, 44195, United States

NOT YET RECRUITING

Ascentage Investigative Site #1174

Mayfield Heights, Ohio, 44124, United States

NOT YET RECRUITING

Ascentage Investigative Site #1139

Portland, Oregon, 97239, United States

NOT YET RECRUITING

Ascentage Investigative Site #1057

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

Ascentage Investigative Site #1022

Pittsburgh, Pennsylvania, 15232, United States

RECRUITING

Ascentage Investigative Site #1063

Chattanooga, Tennessee, 37404, United States

RECRUITING

Ascentage Investigative Site #1089

Nashville, Tennessee, 37203, United States

RECRUITING

Ascentage Investigative Site #1051

Amarillo, Texas, 79124, United States

RECRUITING

Ascentage Investigative Site #1036

Austin, Texas, 78705, United States

RECRUITING

Ascentage Investigative Site #1501

Houston, Texas, 77030, United States

RECRUITING

Ascentage Investigative Site #1050

Virginia Beach, Virginia, 23456, United States

RECRUITING

Ascentage Investigative Site #1136

Edmonds, Washington, 98026, United States

RECRUITING

Ascentage Investigative Site #1135

Issaquah, Washington, 98029, United States

RECRUITING

Ascentage Investigative Site #1806

Seattle, Washington, 98104, United States

RECRUITING

Ascentage Investigative Site #1510

Seattle, Washington, 98109, United States

RECRUITING

Ascentage Investigative Site #2107

Campbelltown, New South Wales, 2560, Australia

RECRUITING

Ascentage Investigative Site #2105

Liverpool, New South Wales, 2170, Australia

RECRUITING

Ascentage Investigative Site #2115

Adelaide, South Australia, 5000, Australia

RECRUITING

Ascentage Investigative Site #2106

Perth, Western Australia, 6000, Australia

RECRUITING

Ascentage Investigative Site #5211

Anderlecht, 1070, Belgium

RECRUITING

Ascentage Investigative Site #5212

Gilly, 6060, Belgium

RECRUITING

Ascentage Investigative Site #5208

Kortrijk, 8500, Belgium

RECRUITING

Ascentage Investigative Site #5209

Roeselare, 8800, Belgium

RECRUITING

Ascentage Investigative Site #5210

Yvoir, 5530, Belgium

RECRUITING

Ascentage Investigative Site #8004

Toronto, M5G 2M9, Canada

RECRUITING

Ascentage Investigative Site #5037

Amiens, 80054, France

RECRUITING

Ascentage Investigative Site #5015

Bobigny, 93000, France

RECRUITING

Ascentage Investigative Site #5017

Nice, 06202, France

RECRUITING

Ascentage Investigative Site #5016

Rouen, 76038, France

RECRUITING

Ascentage Investigative Site #5023

Toulouse, 31059, France

RECRUITING

Ascentage Investigative Site #5708

Berlin, 13353, Germany

RECRUITING

Ascentage Investigative Site #5709

Dresden, 01307, Germany

RECRUITING

Ascentage Investigative Site #9118

Bangalore, 560027, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #9120

Haryāna, 122002, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #9102

Haryāna, 124105, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #9110

Hyderabad, 500033, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #9116

Kolkata, 700014, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #9115

Kolkata, 700054, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #9101

New Delhi, 110029, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #9103

New Delhi, 110076, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #9119

Pune, 411001, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #9113

Thiruvananthapuram, 695011, India

ACTIVE NOT RECRUITING

Ascentage Investigative Site #5535

Bologna, 40138, Italy

RECRUITING

Ascentage Investigative Site #5534

Candiolo, 10060, Italy

RECRUITING

Ascentage Investigative Site #5527

Catania, 95123, Italy

RECRUITING

Ascentage Investigative Site #5523

Lecce, 73100, Italy

RECRUITING

Ascentage Investigative Site #5529

Meldola, 47014, Italy

RECRUITING

Ascentage Investigative Site #5537

Messina, 98124, Italy

NOT YET RECRUITING

Ascentage Investigative Site #5553

Milan, 20122, Italy

RECRUITING

Ascentage Investigative Site #5530

Naples, 80131, Italy

RECRUITING

Ascentage Investigative Site #5524

Novara, 28100, Italy

RECRUITING

Ascentage Investigative Site #5525

Padova, 35128, Italy

RECRUITING

Ascentage Investigative Site #5526

Pisa, 56126, Italy

RECRUITING

Ascentage Investigative Site #5528

Roma, 00144, Italy

RECRUITING

Ascentage Investigative Site #5522

Roma, 00161, Italy

RECRUITING

Ascentage Investigative Site #5510

Roma, 00168, Italy

NOT YET RECRUITING

Ascentage Investigative Site #5552

Torino, 10126, Italy

NOT YET RECRUITING

Ascentage Investigative Site #5521

Torino, 10128, Italy

RECRUITING

Ascentage Investigative Site #5536

Varese, 21100, Italy

RECRUITING

Ascentage Investigative Site #8101

Ehime, 790-8524, Japan

RECRUITING

Ascentage Investigative Site #8102

Kyoto, 602-8566, Japan

RECRUITING

Ascentage Investigative Site #8112

Okayama, 701-1192, Japan

RECRUITING

Ascentage Investigative Site #8105

Osaka, 565-0871, Japan

RECRUITING

Ascentage Investigative Site #8106

Sapporo, 003-0006, Japan

RECRUITING

Ascentage Investigative Site #8107

Sapporo, 060-8648, Japan

RECRUITING

Ascentage Investigative Site #8109

Tochigi, 321-0207, Japan

RECRUITING

Ascentage Investigative Site #8114

Tokyo, 113-8677, Japan

RECRUITING

Ascentage Investigative Site #8117

Tokyo, 130-8575, Japan

RECRUITING

Ascentage Investigative Site #8110

Tokyo, 141-8625, Japan

RECRUITING

Ascentage Investigative Site #8104

Yamagata, 990-9585, Japan

RECRUITING

Ascentage Investigative Site #8103

Yamanashi, 409-3898, Japan

RECRUITING

Ascentage Investigative Site #4213

Gdansk, 80214, Poland

RECRUITING

Ascentage Investigative Site #4212

Gdansk, 80219, Poland

RECRUITING

Ascentage Investigative Site #4207

Katowice, 40519, Poland

RECRUITING

Ascentage Investigative Site #4209

Krakow, 30688, Poland

RECRUITING

Ascentage Investigative Site #4211

Lodz, 93513, Poland

RECRUITING

Ascentage Investigative Site #4214

Torun, 87100, Poland

RECRUITING

Ascentage Investigative Site #4206

Warsaw, 00791, Poland

NOT YET RECRUITING

Ascentage Investigative Site #4210

Wałbrzych, 58309, Poland

RECRUITING

Ascentage Investigative Site #3227

Moscow, 125167, Russia

ACTIVE NOT RECRUITING

Ascentage Investigative Site #3228

Saint Petersburg, 191024, Russia

ACTIVE NOT RECRUITING

Ascentage Investigative Site #3213

Saint Petersburg, 194291, Russia

ACTIVE NOT RECRUITING

Ascentage Investigative Site #3212

Saint Petersburg, 197341, Russia

ACTIVE NOT RECRUITING

Ascentage Investigative Site #6602

Singapore, 117599, Singapore

RECRUITING

Ascentage Investigative Site #6601

Singapore, 168583, Singapore

RECRUITING

Ascentage Investigative Site #8206

Busan, 49201, South Korea

RECRUITING

Ascentage Investigative Site #8207

Busan, 49241, South Korea

RECRUITING

Ascentage Investigative Site #8204

Gyeonggi-do, 13620, South Korea

RECRUITING

Ascentage Investigative Site #8201

Seoul, 03080, South Korea

RECRUITING

Ascentage Investigative Site #8202

Seoul, 05505, South Korea

RECRUITING

Ascentage Investigative Site #8205

Seoul, 06351, South Korea

RECRUITING

Ascentage Investigative Site #8203

Seoul, 06591, South Korea

RECRUITING

Ascentage Investigative Ste #8208

Uijeongbu-si, 11749, South Korea

RECRUITING

Ascentage Investigative Site #6015

Badalona, 08916, Spain

RECRUITING

Ascentage Investigative Site #6020

Barcelona, 08035, Spain

RECRUITING

Ascentage Investigative Site #6047

Elche, 03293, Spain

RECRUITING

Ascentage Investigative Site #6014

L'Hospitalet de Llobregat, 08906, Spain

RECRUITING

Ascentage Investigative Site #6035

Madrid, 28006, Spain

RECRUITING

Ascentage Investigative Site #6013

Madrid, 28007, Spain

RECRUITING

Ascentage Investigative Site #6033

Madrid, 28031, Spain

RECRUITING

Ascentage Investigative Site #6011

Madrid, 28041, Spain

RECRUITING

Ascentage Investigative Site #6032

Madrid, 28046, Spain

RECRUITING

Ascentage Investigative Site #6037

Majadahonda, 28222, Spain

RECRUITING

Ascentage Investigative Site #6012

Málaga, 29010, Spain

RECRUITING

Ascentage Investigative Site #6039

Málaga, 29010, Spain

RECRUITING

Ascentage Investigative Site #6051

Murcia, 30120, Spain

NOT YET RECRUITING

Ascentage Investigative Site #6036

Ourense, 32005, Spain

RECRUITING

Ascentage Investigative Site #6038

Valencia, 46017, Spain

RECRUITING

Ascentage Investigative Site #6041

Zaragoza, 50009, Spain

RECRUITING

Ascentage Investigative Site #9216

Adapazarı, 54100, Turkey (Türkiye)

RECRUITING

Ascentage Investigative Site #9218

Ankara, 06050, Turkey (Türkiye)

RECRUITING

Ascentage Investigative Site #9204

Ankara, 06170, Turkey (Türkiye)

RECRUITING

Ascentage Investigative Site #9215

Battalgazi, 44210, Turkey (Türkiye)

RECRUITING

Ascentage Investigative Site #9217

Çankaya, 06800, Turkey (Türkiye)

NOT YET RECRUITING

Ascentage Investigative Site #9219

Istanbul, 34452, Turkey (Türkiye)

NOT YET RECRUITING

Ascentage Investigative Site #9205

Kepez, 07025, Turkey (Türkiye)

RECRUITING

Ascentage Investigative Site #9208

Mezitli, 33200, Turkey (Türkiye)

RECRUITING

Ascentage Investigative Site #9213

Ortahisar, 61080, Turkey (Türkiye)

RECRUITING

Ascentage Investigative Site #9214

Samsun, 55270, Turkey (Türkiye)

RECRUITING

Ascentage Investigative Site #9212

Yenimahalle, 06200, Turkey (Türkiye)

RECRUITING

Ascentage Investigative Site #7017

Aberdeen, AB25 2ZN, United Kingdom

RECRUITING

Ascentage Investigative Site #7036

Birmingham, B15 2GW, United Kingdom

RECRUITING

Ascentage Investigative Site #7021

Boston, PE21 9QS, United Kingdom

RECRUITING

Ascentage Investigative Site #7037

Bradford, BD9 6RJ, United Kingdom

RECRUITING

Ascentage Investigative Site #7035

Liverpool, L7 8YA, United Kingdom

RECRUITING

Ascentage Investigative Site #7016

London, SE5 9RS, United Kingdom

RECRUITING

Ascentage Investigative Site #7015

London, W12 0HS, United Kingdom

RECRUITING

Ascentage Investigative Site #7018

Newport, NP20 2UB, United Kingdom

RECRUITING

MeSH Terms

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-Phase

Interventions

olverembatinibbosutinib

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsMyeloproliferative DisordersBone Marrow DiseasesHematologic DiseasesHemic and Lymphatic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Elias Jabbour, M.D.

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ascentage Clinical Operations

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Part A (285 patients): Randomization to olverembatinib or bosutinib at 2:1 ratio. Part B in patients with T315I mutation (48 patients): Single-arm part; all enrolled patients receive olverembatinib.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR
Expanded Access
Yes

Study Record Dates

First Submitted

May 16, 2024

First Posted

May 21, 2024

Study Start

February 5, 2024

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

July 10, 2028

Last Updated

September 15, 2026

Record last verified: 2026-09

Locations